Drugs / Furmonertini
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07229729 Comparator | Nov 2025 → Oct 2026 expected | non-small cell lung carcinoma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Furmonertini | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07229729 ↗ |